SAFLUTAN

Indications

• Raised intraocular pressure in open-angle glaucoma
• Ocular hypertension

Dosage

Children: For paediatric dosing, refer to the BNF for Children.

Adults: Apply once daily, preferably in the evening, as 1 drop to the affected eye(s).

Mechanism of action

Tafluprost acid acts as a selective agonist for the FP receptor, believed to reduce intraocular pressure by enhancing the outflow of aqueous humor. The predominant mechanism for this effect is increased uveoscleral outflow, which helps to alleviate elevated pressure within the eye.

Pharmacodynamics

Tafluprost is a novel prostaglandin analog that exhibits a strong affinity for the fluoroprostaglandin (FP) receptor PGF2α, approximately 12 times higher than latanoprost's carboxylic acid. This selectivity contributes to its efficacy in lowering intraocular pressure, as it minimizes interactions with other receptor types, reducing the likelihood of side effects associated with non-selective agents.

Pharmacokinetics

After topical administration, tafluprost is rapidly absorbed and metabolized in the eye. Peak IOP-lowering effects are typically observed within 12 hours of administration. The drug undergoes hydrolysis to its active form, tafluprost acid, which is responsible for its therapeutic effects. Systemic absorption is minimal, thus limiting systemic side effects.

Contra-indications

• Active herpes simplex keratitis
• History of recurrent herpetic keratitis associated with prostaglandin analogues

Adverse effects

• Eye irritation
• Excessive watering of the eyes
• Headache
• Dizziness
• Chest pain
• Dyspnoea
• Palpitations
• Myalgia
• Arthralgia

Interactions

• Do not use with thiomersal-containing preparations within 5 minutes

Precautions

• Angle-closure glaucoma
• Aphakia
• Asthma
• Contact lens wearers
• History of significant respiratory disorders
• Peri-operative period of cataract surgery
• Risk factors for uveitis

Pregnancy

Manufacturer advises to avoid use during pregnancy.

Breast-feeding

May be present in milk; manufacturer advises caution.

Storage

Store at room temperature, protect from light.

Formulations

• Tafluprost 0.0015% eye drops (0.15 mg/ml)
• Preservative-free unit dose eye drops

Mechanism of action

Tafluprost acid is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and humans suggest that the main mechanism of action is increased uveoscleral outflow.

Pharmacodynamics

Tafluprost is a novel prostaglandin analog with a high affinity for the fluoroprostaglandin (FP) receptor PGF2α. Tafluprost has an affinity for the FP receptor that is approximately 12 times higher than that of the carboxylic acid of latanoprost, but with almost no potential to bind to other receptors.